Michael J. Pishvaian
机构：Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center · ORCID：0000-0002-1165-9041
发表论文 544 篇 · 总被引 9897 次 · h-index 50
代表论文
- PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer (2025 · Journal of Clinical Oncology · 被引 29)
- Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer (2025 · Journal of Clinical Oncology · 被引 3)
- Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics (2025 · Seminars in Radiation Oncology · 被引 2)
- Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial (2026 · Nature Communications · 被引 1)
- Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001. (2026 · Journal of Clinical Oncology · 被引 1)
- POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer (2026 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)